Molecular mechanism for pancreatic β-cell dysfunction and atherosclerosis

Area of Science:

• Endocrinology
• Metabolic Diseases
• Pharmacology

Background:

• Chronic hyperglycemia impairs pancreatic beta-cell function, leading to glucose toxicity.
• Diabetic conditions increase oxidative stress and down-regulate insulin gene transcription factors and incretin receptors.
• Incretin receptor expression is also reduced in arterial cells, potentially linking to atherosclerosis.

Purpose of the Study:

• To investigate the protective effects of SGLT2 inhibitors and incretin-based drugs on beta-cell function under diabetic conditions.
• To explore the role of imeglimin in preserving beta-cell health and mitigating atherosclerosis.
• To understand the relationship between oxidative stress, gene expression, and diabetic complications.

Main Methods:

• Utilized SGLT2 inhibitors to reduce glucose toxicity and observed effects on key factors.
• Assessed the benefits of early-stage incretin-based drug intervention when incretin receptors are preserved.
• Examined the impact of imeglimin on beta-cell mitochondria, insulin granules, and atherosclerosis development.

Main Results:

• SGLT2 inhibitors preserved expression levels of insulin gene transcription factors and incretin receptors, mitigating glucose toxicity.
• Early intervention with incretin-based drugs proved more beneficial when incretin receptor expression was maintained.
• Imeglimin demonstrated positive effects on beta-cell mitochondria and insulin granules, and independently beneficial effects against atherosclerosis.

Conclusions:

• Increased oxidative stress and reduced expression of key factors are linked to pancreatic beta-cell glucose toxicity.
• Incretin-based drugs and imeglimin show promise in combating beta-cell glucose toxicity and preventing atherosclerosis progression.
• Timely introduction of these therapeutic agents is crucial for optimal outcomes in diabetes management.